New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin Like Growth Factor Receptor
May 15th 2008Drug InformationEndocrinology
Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene — p53 — is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
